Effect of latanoprost as adjunctive therapy

Background: Latanoprost may be a useful adjunct in some patients receiving maximum tolerated medical therapy. We report our clinical experience with l atanoprost when added to one or two other glaucoma medications. Methods: Review of the charts of 53 patients with open-angle glaucoma whose intraocular pressure (IOP) was uncontrolled with one or two glaucoma medic ations and who had latanoprost added as a second or third drug. Patients wh ose IOP decreased by 3 mm Hg or more were considered to be responders. Results: The shortest length of follow-up was 2.3 months (median 5.8 months ). Latanoprost was given as a second medication to 35 patients, of whom 22 (63%) responded, with a mean IOP reduction of 6.1 mm Hg (standard deviation [SD] 2.73 mm Hg) (28.7% [SD 12.10%]). Of the 18 patients to whom latanopro st was given as a third medication, 10 (56%) responded, with a mean IOP red uction of 6.3 mm Hg (SD 3.86 mm Hg) (24.5% [SD 10.12%]). Interpretation: Latanoprost provides additional IOP reduction in some patie nts with open-angle glaucoma when added to one or two other glaucoma medica tions.